Aspira Women’s Health Announces Late-Breaking Poster Presentation at the Upcoming 71st Annual Scientific Meeting for the Society for Reproductive Investigation (SRI)
AUSTIN, Texas, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced a late-breaking poster presentation at the upcoming 71st Annual Scientific Meeting for the Society for Reproductive Investigation (SRI) to be held in Vancouver, Canada on March 12-16, 2024.
- AUSTIN, Texas, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced a late-breaking poster presentation at the upcoming 71st Annual Scientific Meeting for the Society for Reproductive Investigation (SRI) to be held in Vancouver, Canada on March 12-16, 2024.
- “Endometriomas are among the most common forms of endometriosis, impacting millions of women.
- The presentation of data that is foundational to our EndoCheckSM offering at this distinguished conference is a major milestone for our plan to launch the first noninvasive diagnostic test for this debilitating disease,” said Nicole Sandford, Chief Executive Officer of Aspira.
- Details of the poster presentation are as follows: